{"product_id":"edwards-ansoff-matrix","title":"Edwards Lifesciences Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Amsoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Edwards Lifesciences Amsoff Matrix Analysis gives you a fast, structured view of the company’s growth options across market penetration, market development, product development, and diversification. This page already shows a real preview of the actual analysis, so you can review the content and format before buying. Purchase the full version to get the complete ready-to-use report instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDefend the 1M-Patient SAPIEN Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences defends share in mature TAVR markets by leaning on the SAPIEN base, which has treated more than 1 million patients by 2025. That scale drives surgeon familiarity and hospital standardization, so the default choice stays sticky. Even when rivals cut price, switching is harder because SAPIEN is already embedded in workflow and outcomes data.\u003c\/p\u003e\n\u003cp\u003eIn 2025, that installed base remained a core moat for Edwards Lifesciences’ TAVR franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWin More Cases Through Heart-Team Conversion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences wins by moving severe aortic stenosis patients from diagnosis to heart-team review faster, because the eligible pool is already medically identifiable. In a market where treatment timing decides volume, each added referral can lift cath lab conversions and market share. The payoff is procedural, not just unit sales: more patients reaching TAVR evaluation means more of the estimated 1 in 8 older adults with AS getting treated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand PASCAL Adoption in 2 Valve Repairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences can push PASCAL from 1 repair use case to 2, mitral and tricuspid, inside the same structural-heart account. That lets the same physician and cath lab team add a second therapy without rebuilding workflow, which lowers adoption friction and raises wallet share. In 2025, the strategy matters because each incremental valve program deepens penetration across the same hospital network.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeep Surgical Valve Share with RESILIA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdwards Lifesciences defends its surgical valve base with RESILIA tissue, led by INSPIRIS RESILIA and KONECT RESILIA. The pair keeps surgeons in a familiar implant workflow while offering a durable tissue option.\u003c\/p\u003e\n\u003cp\u003eThat matters in fiscal 2025 because TAVR still drives the growth story, but OR presence protects account share and future valve placements. In market penetration terms, Edwards Lifesciences is using RESILIA to hold the line in surgery while its transcatheter business expands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeepen Critical-Care Penetration in ICUs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdwards Lifesciences deepens ICU penetration by selling HemoSphere and Acumen into existing critical-care accounts, so growth comes from higher share of wallet, not just new installs. The model leans on recurring disposables, monitoring upgrades, and clinician training, which lifts retention and makes hospital revenue more predictable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdwards grows TAVR share as SAPIEN tops 1M patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences lifts market penetration by converting more severe aortic stenosis patients into TAVR, using a SAPIEN base that has treated more than 1 million patients by 2025 and stays sticky in hospital workflows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003eFact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAPIEN base\u003c\/td\u003e\n\u003ctd\u003e1M+ patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAS pool\u003c\/td\u003e\n\u003ctd\u003e1 in 8 older adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRule\u003c\/td\u003e\n\u003ctd\u003eMore referrals, more conversions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nOutlines Edwards Lifesciences’s growth strategy across market penetration, market development, product development, and diversification.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nHelps Edwards Lifesciences quickly clarify growth options and reduce strategy confusion with a clean, at-a-glance Ansoff Matrix.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaunch EVOQUE Beyond the U.S.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences is extending EVOQUE beyond the U.S. as transcatheter tricuspid valve replacement moves from early use to broader adoption. In TRISCEND II, 572 patients were randomized, showing the clinical base now supports a true geography-led rollout, which is classic market development because the product stays the same while access expands. Europe is the clearest next market because advanced structural-heart centers can absorb the therapy fastest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroaden Access Across Europe and Japan\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences is widening structural-heart access across Europe and Japan, where catheter-based valve therapy still has room to grow. Japan’s 65+ population is about 29%, and Europe’s is about 21%, so the need for transcatheter aortic valve replacement stays high. Entry is staged because regulatory reviews and local reimbursement often take 12 to 24 months. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuild Share in China and Other Large Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences is building share in China and other large systems where structural-heart use is still early but rising fast; China has 1.4 billion people and a huge hospital base, so even small penetration can add meaningful volume.\u003c\/p\u003e\n\u003cp\u003eThe play is access, not redesign: reimbursement, physician training, and cath lab readiness decide adoption more than the device itself.\u003c\/p\u003e\n\u003cp\u003eThat means clinical data opens the door, but local coverage and training partnerships drive 2025-era growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExport Critical-Care Tools into New Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdwards Lifesciences can push HemoSphere and Acumen into new hospital networks beyond its legacy base, and the fit is strong because ICU hemodynamic monitoring is needed in most large centers. In 2025, Edwards Lifesciences still had a broad installed base to build on, so each new win can create repeat disposable pull-through and multi-year account value. This is a clean market-development play: same products, new hospitals, and more recurring revenue per site.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnter More Valve Centers Through Distributed Training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdwards Lifesciences can grow geographically by adding authorized valve centers one hospital at a time, not just by winning national approvals. Training, proctoring, and field support help each new site clear the first case blocks, which matters in regions where a few elite centers still set the pace.\u003c\/p\u003e\n\u003cp\u003eThis market-development path fits structural heart care in 2025 because access often expands through surgeon confidence and repeat volume, not fast lab buildouts. It lets Edwards Lifesciences turn one strong center into a local network and widen reach without waiting for a full market reset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVOQUE rollout rides approvals, training, and deep aging demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences is pushing EVOQUE into new geographies, so market development is mainly about approvals, reimbursement, and site training. TRISCEND II enrolled 572 patients, giving a strong base for rollout. Japan’s 65+ share is 29% and Europe’s is 21%, so demand for transcatheter valve care stays deep.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTRISCEND II\u003c\/td\u003e\n\u003ctd\u003e572 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan 65+\u003c\/td\u003e\n\u003ctd\u003e29%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEurope 65+\u003c\/td\u003e\n\u003ctd\u003e21%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eEdwards Lifesciences Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Edwards Lifesciences Amsoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full Edwards Lifesciences report you'll get. Purchase unlocks the complete in-depth version.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing a live preview of the actual Edwards Lifesciences analysis file. The full document becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvance the EVOQUE Tricuspid Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvance the EVOQUE Tricuspid Platform strengthens Edwards Lifesciences' product development push in structural heart, adding depth beyond aortic disease. EVOQUE is the first major transcatheter tricuspid replacement system in its portfolio, and the tricuspid regurgitation market is large, with about 1.6 million U.S. patients affected. Continued upgrades in delivery, sizing, and usability should help adoption through 2026, while keeping Edwards Lifesciences positioned in a new growth lane.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUpgrade SAPIEN with RESILIA Tissue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences is upgrading the SAPIEN line by pairing platform refinements with RESILIA tissue, aiming to extend valve durability and make long-term performance easier for physicians to trust. That matters in TAVR, where stronger durability can support referral choices, payer confidence, and repeat use versus older-generation valves. The move strengthens differentiation by tying SAPIEN to a better lifetime value story, not just a one-time implant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand PASCAL for 2 Repair Pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences is expanding PASCAL across 2 repair pathways: mitral and tricuspid. That platform design lets Edwards Lifesciences serve 2 anatomy sets with 1 technology stack, which should raise R\u0026amp;D reuse and lower the cost of each new iteration. It also gives field teams more reason to stay inside 1 account, since the same hospital can adopt PASCAL in both valve programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRefresh Surgical Portfolio with New Conduits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdwards Lifesciences uses KONECT RESILIA and MITRIS RESILIA to refresh its surgical portfolio and keep open-heart surgery relevant as transcatheter therapies grow. This product development move is about continuity: it protects surgeon relationships and the company’s valve franchise, not a disruptive reset. In 2025, that mattered because Edwards still had to serve both minimally invasive and open surgery needs in one cardiac market.\u003c\/p\u003e\n\u003cp\u003eThe two RESILIA conduits and valves help Edwards answer demand for durable surgical options while supporting premium pricing and repeat hospital use. That makes product development a defense of share and margin, not just a new launch cycle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhance HemoSphere with Decision Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn FY2025, Edwards Lifesciences reported about $5.9 billion in net sales, and adding analytics to HemoSphere and Acumen helps shift critical care from hardware sales to software-led insight. Better alarms, trend views, and workflow support can make ICU teams faster and can strengthen the buying case when hospitals compare total cost of care. This fits an Ansoff product development move: sell more value to the same ICU base without changing the core customer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdwards Doubles Down on Structural Heart in FY2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Edwards Lifesciences kept product development focused on structural heart, especially EVOQUE, PASCAL, and RESILIA-based valves. The tricuspid market is large, with about 1.6 million U.S. patients affected, so new delivery and usability upgrades can support adoption. In FY2025, Edwards Lifesciences posted about $5.9 billion in net sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 focus\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEVOQUE\u003c\/td\u003e\n\u003ctd\u003eTricuspid replacement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. TR patients\u003c\/td\u003e\n\u003ctd\u003e1.6 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e$5.9 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMove from Aortic to Tricuspid Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences is moving beyond aortic care into tricuspid therapy with EVOQUE, adding a second structural-heart growth engine. Tricuspid replacement is a new disease state and workflow, so it pulls in different physicians, evidence, and adoption curves than the aortic franchise. That is the clearest adjacent diversification in Edwards Lifesciences’s portfolio, with EVOQUE already advancing a market that had far less established therapy than TAVR.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlend Devices with Software-Led ICU Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences is moving from implanted valves into software-led ICU care, so this is related diversification, not a random bet. HemoSphere and Acumen widen the model by pairing disposables, monitoring, and analytics, which can lift recurring revenue and deepen hospital ties. In 2025, that shift matters because ICU decision tools sit in a much larger critical-care spending pool than a single-device sale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReach Surgical and Catheter-Based Markets Together\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences sells both surgical valves and transcatheter therapies, so it is not tied to one procedure path. In FY2025, that mix helps balance demand as TAVR and transcatheter repair grow alongside the surgical portfolio. It also lowers risk if one reimbursement cycle or clinical preference shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand into New Anatomy-Plus-Platform Combinations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdwards Lifesciences is expanding by pairing platform technology with new anatomies, especially tricuspid valves plus repair and replacement tools. That turns one R\u0026amp;D base into several growth paths, so the same clinical know-how can support more than one product line. It is broader than simple line extension, but it still stays tied to Edwards Lifesciences’ core cardiovascular expertise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUse Partnerships to Add Adjacent Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdwards Lifesciences can diversify by partnering in imaging, navigation, and procedural workflow, which extends its 2025 structural-heart base without moving into unrelated markets. That fits a focused medtech model: add tools that improve TAVR, TMTT, and case efficiency, not a big bet like a broad acquisition. With 2025 revenue still in the $5 billion-plus range, partnership-led diversification is the cleaner path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdwards Lifesciences Expands Carefully Into New Adjacent Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdwards Lifesciences’ diversification in FY2025 is mainly adjacent: EVOQUE expands into tricuspid replacement, while HemoSphere and Acumen push into ICU monitoring software. That adds new disease states and revenue streams without leaving structural heart and critical care. FY2025 revenue stayed above $5 billion, so this is disciplined diversification, not a leap.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 move\u003c\/th\u003e\n\u003cth\u003eType\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEVOQUE\u003c\/td\u003e\n\u003ctd\u003eRelated\u003c\/td\u003e\n\u003ctd\u003eNew tricuspid market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemoSphere\u003c\/td\u003e\n\u003ctd\u003eRelated\u003c\/td\u003e\n\u003ctd\u003eICU software plus disposables\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53648539418966,"sku":"edwards-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/edwards-ansoff-analysis.webp?v=1778882493","url":"https:\/\/balancedscorecardexamples.com\/products\/edwards-ansoff-matrix","provider":"Balanced Scorecard","version":"1.0","type":"link"}